Literature DB >> 27177149

Safflower polysaccharide induces NSCLC cell apoptosis by inhibition of the Akt pathway.

Jian-Ying Li1, Jun Yu2, Xu-Sheng Du3, Hui-Min Zhang3, Bo Wang3, Hua Guo3, Jie Bai3, Juan-Hong Wang4, An Liu3, Yi-Li Wang1.   

Abstract

Lung cancer is the leading cause of cancer death in the world. Safflower polysaccharide (SPS) has been used for the improvement of immunomodulatory activities and treatment of cancers. However, studies on the effect of SPS on the progression of lung cancer have rarely been reported. To study the antitumor effect of SPS on human lung cancer and its potential mechanism, non-small cell lung cancer cell lines (NSCLC), A549 and YTMLC-90 were treated with SPS at various concentrations ranging from 0.04 to 2.56 mg/ml and BALB/c nude tumor-bearing mice were injected intraperitoneally with SPS at concentrations ranging from 15 to 135 mg/kg. Results showed that SPS suppressed the proliferation of A549 and YTMLC-90 cells and induced apoptosis by increasing mRNA levels of bax and caspase-3, and inhibited tumor growth in vivo. SPS induced cell cycle arrest in the G2/M phase by decreasing the expression of cdc25B and cyclin B1. Moreover, SPS decreased the expression of Akt, p-Akt and PI3K. In mice, SPS injection enhanced immunomodulatory activities by increasing levels of TNF-α and IL-6 in tumor-bearing mice. Our findings suggest that SPS suppresses tumor growth by enhancing immunomodulatory activities and blocking the PI3K/Akt pathway. This study provides new insight into the anticancer mechanism of SPS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27177149     DOI: 10.3892/or.2016.4784

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Pharmacological Activities of Safflower Yellow and Its Clinical Applications.

Authors:  Yan Chen; Meifeng Li; Jiayu Wen; Xiaoqi Pan; Zixin Deng; Junren Chen; Guanru Chen; Lei Yu; Yunli Tang; Gangmin Li; Xiaofang Xie; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-27       Impact factor: 2.650

2.  A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.

Authors:  Xiangyu Su; Chanchan Gao; Fangfang Shi; Xiaoyao Feng; Lin Liu; Ding Qu; Cailian Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.

Authors:  Nahathai Dukaew; Kongthawat Chairatvit; Pornsiri Pitchakarn; Arisa Imsumran; Jirarat Karinchai; Wirote Tuntiwechapikul; Ariyaphong Wongnoppavich
Journal:  Oncol Rep       Date:  2020-07-31       Impact factor: 3.906

Review 4.  Modulation of Apoptosis by Plant Polysaccharides for Exerting Anti-Cancer Effects: A Review.

Authors:  Qing-Xia Gan; Jin Wang; Ju Hu; Guan-Hua Lou; Hai-Jun Xiong; Cheng-Yi Peng; Qin-Wan Huang
Journal:  Front Pharmacol       Date:  2020-05-27       Impact factor: 5.810

5.  Safflower polysaccharide inhibits the development of tongue squamous cell carcinoma.

Authors:  Haiyan Zhou; Jing Yang; Chuhan Zhang; Yuwei Zhang; Rui Wang; Xiao Li; Shuainan Zhang
Journal:  World J Surg Oncol       Date:  2018-08-13       Impact factor: 2.754

6.  Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere.

Authors:  Pengkai Ma; Jianhua Chen; Haixian Qu; Ye Li; Xiaohui Li; Xuemei Tang; Zhigang Song; Hainan Xin; Jinbang Zhang; Jingxue Nai; Zhiping Li; Zhijun Wang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.